- Home
- NERV vs HTCR Comparison
NERV vs HTCR Comparison
Compare NERV & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- HTCR
- Stock Information
- Founded
- NERV 2007
- HTCR 2009
- Country
- NERV United States
- HTCR Japan
- Employees
- NERV N/A
- HTCR N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- HTCR EDP Services
- Sector
- NERV Health Care
- HTCR Technology
- Exchange
- NERV Nasdaq
- HTCR Nasdaq
- Market Cap
- NERV 12.6M
- HTCR 12.8M
- IPO Year
- NERV 2014
- HTCR 2022
- Fundamental
- Price
- NERV $1.77
- HTCR $0.52
- Analyst Decision
- NERV Hold
- HTCR
- Analyst Count
- NERV 1
- HTCR 0
- Target Price
- NERV $5.00
- HTCR N/A
- AVG Volume (30 Days)
- NERV 12.2K
- HTCR 194.5K
- Earning Date
- NERV 08-05-2025
- HTCR 08-13-2025
- Dividend Yield
- NERV N/A
- HTCR 3.92%
- EPS Growth
- NERV N/A
- HTCR N/A
- EPS
- NERV 0.83
- HTCR N/A
- Revenue
- NERV N/A
- HTCR $28,947,523.00
- Revenue This Year
- NERV N/A
- HTCR N/A
- Revenue Next Year
- NERV N/A
- HTCR $8.59
- P/E Ratio
- NERV $2.18
- HTCR N/A
- Revenue Growth
- NERV N/A
- HTCR 59.42
- 52 Week Low
- NERV $1.15
- HTCR $0.49
- 52 Week High
- NERV $3.50
- HTCR $3.38
- Technical
- Relative Strength Index (RSI)
- NERV 57.10
- HTCR 44.82
- Support Level
- NERV $1.62
- HTCR $0.54
- Resistance Level
- NERV $1.83
- HTCR $0.55
- Average True Range (ATR)
- NERV 0.09
- HTCR 0.03
- MACD
- NERV -0.00
- HTCR 0.00
- Stochastic Oscillator
- NERV 64.29
- HTCR 44.83
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About HTCR Heartcore Enterprises Inc.
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.